RxDoctor Payments Data

Mohammad Rizvi, DO

Cardiovascular Disease · Clermont, FLNPI 1992151138

Payments from drug & device makers

$1,300in general payments, 2019–2025

Across 31 payments — averaging $41.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$205
  • AstraZeneca$184
  • Kestra Medical Technology Services, Inc.$184
  • Novartis$183
  • Amgen$168
  • Cvrx, Inc.$125
  • plus $251 from 4 others

What the payments were for

  • Food & beverage$1,20092%
  • Education$1008%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,300 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$236,873
Medicare patients
739
Services billed
2,431

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$151,876
XareltoRivaroxaban51$63,467
EntrestoSacubitril/Valsartan36$48,736
JardianceEmpagliflozin17$21,509
BrilintaTicagrelor26$16,653
FarxigaDapagliflozin Propanediol14$8,269
VascepaIcosapent Ethyl14$7,989
Atorvastatin Calcium121$1,396
Olmesartan Medoxomil67$1,391
Metoprolol Succinate112$1,195
Rosuvastatin Calcium66$1,090
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide33$963
Losartan Potassium116$738
Carvedilol81$701
Amlodipine Besylate92$695

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$151,876119 claims
NovartisEntresto$183$48,73636 claims
AstraZenecaBrilinta, Farxiga$184$24,92340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Clermont

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →